Compare WATT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | SPRO |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 73.4M |
| IPO Year | 2014 | 2017 |
| Metric | WATT | SPRO |
|---|---|---|
| Price | $11.22 | $1.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 138.9K | ★ 814.5K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | $1,154,009.00 | ★ $66,802,000.00 |
| Revenue This Year | $167.69 | N/A |
| Revenue Next Year | $148.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $3.62 | $1.08 |
| 52 Week High | $36.98 | $3.08 |
| Indicator | WATT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 49.50 |
| Support Level | $10.17 | $1.12 |
| Resistance Level | $12.19 | $1.28 |
| Average True Range (ATR) | 0.81 | 0.08 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 5.88 | 22.58 |
Energous Corp has developed scalable, over-the-air Wireless Power Network (WPN) technology that integrates semiconductor chipsets, software controls, hardware designs, and antenna systems to enable radio frequency (RF)-based charging for ambient Internet of Things (ambient IoT) devices, transforming supply chain capabilities from limited tracking to overall business intelligence. The WPN technology consists of transmitter systems, receiver integrated circuits, and supporting software designed to deliver power and data to battery-free IoT devices across a range of operating distances and power levels. Its applications include retail sensors, electronic shelf labels (ESLs), asset trackers, air quality monitors, motion detectors, and other monitoring solutions.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.